Tilray Brands (TLRY) Research & Development (2017 - 2026)
Tilray Brands (TLRY) posted Research & Development of $1.0 million for Q1 2026, down 21.52% on a QoQ basis from $1.3 million in Q4 2025, and down 7.82% year-over-year from $1.1 million in Q1 2025.
Tilray Brands (TLRY) Research & Development (2017 - 2026) Analysis & Trends
Tilray Brands' Research & Development history runs 10 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- Quarterly Research & Development fell 7.82% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $2.4 million (up 230.32% YoY) and the FY2025 annual result came in at $284000.0, down 55.28% from the prior year.
- Research & Development was $1.0 million for Q1 2026 at Tilray Brands, down from $1.3 million in the prior quarter.
- Across five years, Research & Development topped out at $1.3 million in Q4 2025 and bottomed at -$3.1 million in Q2 2024.
- A 5-year average of $138882.4 and a median of $105000.0 in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slumped 179.28% — and 2025, when it surged 2053.33%.
- Tilray Brands' Research & Development stood at $1.2 million in 2022, then plunged by 95.41% to $56000.0 in 2023, then gained by 7.14% to $60000.0 in 2024, then jumped by 2053.33% to $1.3 million in 2025, then decreased by 21.52% to $1.0 million in 2026.
- Business Quant data shows TLRY's Research & Development at $1.0 million in Q1 2026, $1.3 million in Q4 2025, and $41000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Tilray Brands | 439.44 Mn | 379.24 Mn | 54.95 Mn | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 1.01 Mn |
| Nov 30, 2025 | 1.29 Mn |
| Aug 31, 2025 | 41,000.00 |
| May 31, 2025 | 34,000.00 |
| Feb 28, 2025 | 1.10 Mn |
| Nov 30, 2024 | 60,000.00 |
| Aug 31, 2024 | 105,000.00 |
| May 31, 2024 | -3.09 Mn |
| Feb 29, 2024 | 1.25 Mn |
| Nov 30, 2023 | 56,000.00 |
| Aug 31, 2023 | 79,000.00 |
| May 31, 2023 | -2.80 Mn |
| Feb 28, 2023 | 1.10 Mn |
| Nov 30, 2022 | 1.22 Mn |
| Aug 31, 2022 | 1.16 Mn |
| May 31, 2022 | -1.36 Mn |
| Feb 28, 2022 | 1.10 Mn |
| Nov 30, 2021 | 515,000.00 |
| Aug 31, 2021 | 785,000.00 |
| May 31, 2021 | 1.71 Mn |